Gemcitabine Hydrochloride for Injection - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512247114

Publication Date:

December 9, 2024

Pages:

131

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Gemcitabine Hydrochloride for Injection was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Gemcitabine Hydrochloride for Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gemcitabine Hydrochloride for Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Gemcitabine Hydrochloride for Injection was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Gemcitabine Hydrochloride for Injection include Sun Pharmaceutical Industries, Tapi Teva, Shilpa Medicare, Huachu Industrial, Jinkang Pharmaceutical Technology, Jierui Pharmaceutical, HISUN, FUAN PHARMACEUTICAL and Zhendong Group, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gemcitabine Hydrochloride for Injection, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Gemcitabine Hydrochloride for Injection by region & country, by Type, and by Application.
The Gemcitabine Hydrochloride for Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gemcitabine Hydrochloride for Injection.
Market Segmentation
By Company
Sun Pharmaceutical Industries
Tapi Teva
Shilpa Medicare
Huachu Industrial
Jinkang Pharmaceutical Technology
Jierui Pharmaceutical
HISUN
FUAN PHARMACEUTICAL
Zhendong Group
CHIATAI QINGJIANG
Segment by Type:
200 mg
1000 mg
Segment by Application
Non-Small Cell Lung Cancer
Pancreatic Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gemcitabine Hydrochloride for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Gemcitabine Hydrochloride for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Gemcitabine Hydrochloride for Injection in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Gemcitabine Hydrochloride for Injection Product Introduction
1.2 Global Gemcitabine Hydrochloride for Injection Market Size Forecast
1.2.1 Global Gemcitabine Hydrochloride for Injection Sales Value (2019-2030)
1.2.2 Global Gemcitabine Hydrochloride for Injection Sales Volume (2019-2030)
1.2.3 Global Gemcitabine Hydrochloride for Injection Sales Price (2019-2030)
1.3 Gemcitabine Hydrochloride for Injection Market Trends & Drivers
1.3.1 Gemcitabine Hydrochloride for Injection Industry Trends
1.3.2 Gemcitabine Hydrochloride for Injection Market Drivers & Opportunity
1.3.3 Gemcitabine Hydrochloride for Injection Market Challenges
1.3.4 Gemcitabine Hydrochloride for Injection Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gemcitabine Hydrochloride for Injection Players Revenue Ranking (2023)
2.2 Global Gemcitabine Hydrochloride for Injection Revenue by Company (2019-2024)
2.3 Global Gemcitabine Hydrochloride for Injection Players Sales Volume Ranking (2023)
2.4 Global Gemcitabine Hydrochloride for Injection Sales Volume by Company Players (2019-2024)
2.5 Global Gemcitabine Hydrochloride for Injection Average Price by Company (2019-2024)
2.6 Key Manufacturers Gemcitabine Hydrochloride for Injection Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Gemcitabine Hydrochloride for Injection Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Gemcitabine Hydrochloride for Injection
2.9 Gemcitabine Hydrochloride for Injection Market Competitive Analysis
2.9.1 Gemcitabine Hydrochloride for Injection Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Gemcitabine Hydrochloride for Injection Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gemcitabine Hydrochloride for Injection as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 200 mg
3.1.2 1000 mg
3.2 Global Gemcitabine Hydrochloride for Injection Sales Value by Type
3.2.1 Global Gemcitabine Hydrochloride for Injection Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gemcitabine Hydrochloride for Injection Sales Value, by Type (2019-2030)
3.2.3 Global Gemcitabine Hydrochloride for Injection Sales Value, by Type (%) (2019-2030)
3.3 Global Gemcitabine Hydrochloride for Injection Sales Volume by Type
3.3.1 Global Gemcitabine Hydrochloride for Injection Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Gemcitabine Hydrochloride for Injection Sales Volume, by Type (2019-2030)
3.3.3 Global Gemcitabine Hydrochloride for Injection Sales Volume, by Type (%) (2019-2030)
3.4 Global Gemcitabine Hydrochloride for Injection Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Non-Small Cell Lung Cancer
4.1.2 Pancreatic Cancer
4.1.3 Breast Cancer
4.1.4 Others
4.2 Global Gemcitabine Hydrochloride for Injection Sales Value by Application
4.2.1 Global Gemcitabine Hydrochloride for Injection Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gemcitabine Hydrochloride for Injection Sales Value, by Application (2019-2030)
4.2.3 Global Gemcitabine Hydrochloride for Injection Sales Value, by Application (%) (2019-2030)
4.3 Global Gemcitabine Hydrochloride for Injection Sales Volume by Application
4.3.1 Global Gemcitabine Hydrochloride for Injection Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Gemcitabine Hydrochloride for Injection Sales Volume, by Application (2019-2030)
4.3.3 Global Gemcitabine Hydrochloride for Injection Sales Volume, by Application (%) (2019-2030)
4.4 Global Gemcitabine Hydrochloride for Injection Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Gemcitabine Hydrochloride for Injection Sales Value by Region
5.1.1 Global Gemcitabine Hydrochloride for Injection Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gemcitabine Hydrochloride for Injection Sales Value by Region (2019-2024)
5.1.3 Global Gemcitabine Hydrochloride for Injection Sales Value by Region (2025-2030)
5.1.4 Global Gemcitabine Hydrochloride for Injection Sales Value by Region (%), (2019-2030)
5.2 Global Gemcitabine Hydrochloride for Injection Sales Volume by Region
5.2.1 Global Gemcitabine Hydrochloride for Injection Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Gemcitabine Hydrochloride for Injection Sales Volume by Region (2019-2024)
5.2.3 Global Gemcitabine Hydrochloride for Injection Sales Volume by Region (2025-2030)
5.2.4 Global Gemcitabine Hydrochloride for Injection Sales Volume by Region (%), (2019-2030)
5.3 Global Gemcitabine Hydrochloride for Injection Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
5.4.2 North America Gemcitabine Hydrochloride for Injection Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
5.5.2 Europe Gemcitabine Hydrochloride for Injection Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
5.6.2 Asia Pacific Gemcitabine Hydrochloride for Injection Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
5.7.2 South America Gemcitabine Hydrochloride for Injection Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
5.8.2 Middle East & Africa Gemcitabine Hydrochloride for Injection Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gemcitabine Hydrochloride for Injection Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gemcitabine Hydrochloride for Injection Sales Value
6.2.1 Key Countries/Regions Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.2.2 Key Countries/Regions Gemcitabine Hydrochloride for Injection Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.3.2 United States Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.4.2 Europe Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.5.2 China Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.6.2 Japan Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.7.2 South Korea Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.8.2 Southeast Asia Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gemcitabine Hydrochloride for Injection Sales Value, 2019-2030
6.9.2 India Gemcitabine Hydrochloride for Injection Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gemcitabine Hydrochloride for Injection Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Sun Pharmaceutical Industries
7.1.1 Sun Pharmaceutical Industries Company Information
7.1.2 Sun Pharmaceutical Industries Introduction and Business Overview
7.1.3 Sun Pharmaceutical Industries Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Sun Pharmaceutical Industries Gemcitabine Hydrochloride for Injection Product Offerings
7.1.5 Sun Pharmaceutical Industries Recent Development
7.2 Tapi Teva
7.2.1 Tapi Teva Company Information
7.2.2 Tapi Teva Introduction and Business Overview
7.2.3 Tapi Teva Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Tapi Teva Gemcitabine Hydrochloride for Injection Product Offerings
7.2.5 Tapi Teva Recent Development
7.3 Shilpa Medicare
7.3.1 Shilpa Medicare Company Information
7.3.2 Shilpa Medicare Introduction and Business Overview
7.3.3 Shilpa Medicare Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Shilpa Medicare Gemcitabine Hydrochloride for Injection Product Offerings
7.3.5 Shilpa Medicare Recent Development
7.4 Huachu Industrial
7.4.1 Huachu Industrial Company Information
7.4.2 Huachu Industrial Introduction and Business Overview
7.4.3 Huachu Industrial Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Huachu Industrial Gemcitabine Hydrochloride for Injection Product Offerings
7.4.5 Huachu Industrial Recent Development
7.5 Jinkang Pharmaceutical Technology
7.5.1 Jinkang Pharmaceutical Technology Company Information
7.5.2 Jinkang Pharmaceutical Technology Introduction and Business Overview
7.5.3 Jinkang Pharmaceutical Technology Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Jinkang Pharmaceutical Technology Gemcitabine Hydrochloride for Injection Product Offerings
7.5.5 Jinkang Pharmaceutical Technology Recent Development
7.6 Jierui Pharmaceutical
7.6.1 Jierui Pharmaceutical Company Information
7.6.2 Jierui Pharmaceutical Introduction and Business Overview
7.6.3 Jierui Pharmaceutical Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Jierui Pharmaceutical Gemcitabine Hydrochloride for Injection Product Offerings
7.6.5 Jierui Pharmaceutical Recent Development
7.7 HISUN
7.7.1 HISUN Company Information
7.7.2 HISUN Introduction and Business Overview
7.7.3 HISUN Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.7.4 HISUN Gemcitabine Hydrochloride for Injection Product Offerings
7.7.5 HISUN Recent Development
7.8 FUAN PHARMACEUTICAL
7.8.1 FUAN PHARMACEUTICAL Company Information
7.8.2 FUAN PHARMACEUTICAL Introduction and Business Overview
7.8.3 FUAN PHARMACEUTICAL Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.8.4 FUAN PHARMACEUTICAL Gemcitabine Hydrochloride for Injection Product Offerings
7.8.5 FUAN PHARMACEUTICAL Recent Development
7.9 Zhendong Group
7.9.1 Zhendong Group Company Information
7.9.2 Zhendong Group Introduction and Business Overview
7.9.3 Zhendong Group Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Zhendong Group Gemcitabine Hydrochloride for Injection Product Offerings
7.9.5 Zhendong Group Recent Development
7.10 CHIATAI QINGJIANG
7.10.1 CHIATAI QINGJIANG Company Information
7.10.2 CHIATAI QINGJIANG Introduction and Business Overview
7.10.3 CHIATAI QINGJIANG Gemcitabine Hydrochloride for Injection Sales, Revenue and Gross Margin (2019-2024)
7.10.4 CHIATAI QINGJIANG Gemcitabine Hydrochloride for Injection Product Offerings
7.10.5 CHIATAI QINGJIANG Recent Development
8 Industry Chain Analysis
8.1 Gemcitabine Hydrochloride for Injection Industrial Chain
8.2 Gemcitabine Hydrochloride for Injection Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gemcitabine Hydrochloride for Injection Sales Model
8.5.2 Sales Channel
8.5.3 Gemcitabine Hydrochloride for Injection Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Sun Pharmaceutical Industries
Tapi Teva
Shilpa Medicare
Huachu Industrial
Jinkang Pharmaceutical Technology
Jierui Pharmaceutical
HISUN
FUAN PHARMACEUTICAL
Zhendong Group
CHIATAI QINGJIANG

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂